EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Safety, Pharmacokinetics and Antiviral Efficacy of Capsid Assembly Modulator Freethiadine in Healthy Volunteers and Chronic Hepatitis B Patients

Xiaojiao Li, Jia Xu, Jixuan Sun, Jingrui Liu, Min Wu, Hong Zhang, Xiaoxue Zhu, Cuiyun Li, Yingjun Zhang, Jing Zhu, Yujie Chen, Lin Luo und 5 weitere

Liver International · 2025

DOI: 10.1111/liv.16213 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Liver International, 2025. Verfasst von Xiaojiao Li und 16 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Trial Center, the First Hospital of Jilin University, Jilin, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Antiviral Agents, Guanine, Hepatitis B virus. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Sunshine Lake Pharma Co. Ltd, Norman Bethune Program of Jilin University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Freethiadine is a novel hepatitis B virus capsid assembly modulator. Herein, we report the safety, tolerability, pharmacokinetics and 28‐day antiviral activities of freethiadine.

Methods

The study consisted of two parts. Part 1 involved a single‐ascending‐dose, a multiple‐ascending‐dose and a food effect study. Part 2 was a double‐blind, double‐dummy, randomised, entecavir‐controlled, multi‐dose escalation study in chronic hepatitis B (CHB) patients.

Results

A total of 88 healthy subjects and 40 patients with CHB were enrolled in this study. Freethiadine was well tolerated by both healthy subjects and patients. Among freethiadine‐treated patients with CHB, the most common drug‐related adverse event was alanine aminotransferase elevation (28.1%) (mostly grade 1 or 2). Both HEC160208 and its active metabolite, HEC142106, were rapidly absorbed and eliminated in plasma. Food intake did not significantly influence the exposure of either analyte. Following 28 days of treatment, the mean maximum HBV DNA declines from baseline were −2.76, −3.47, −3.56, −2.89 and −2.55 log 10 IU/mL for the 100 mg BID, 200 mg QD, 200 mg BID and 300 mg QD of freethiadine or entecavir control cohorts, respectively; simultaneously, the mean maximum pregenomic RNA (pgRNA) declines from baseline were −1.69, −2.26, −2.07, −1.47 and −0.06 log 10 copies/mL, respectively.

Conclusions

Freethiadine has an acceptable safety profile and favourable antiviral activity in patients with CHB. These results support further investigations of freethiadine for the treatment of chronic HBV infection. Trial Registration www.clinicaltrials.gov identifier NCT05391360; www.chinadrugtrials.org.cn identifier CTR20212114

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicAntiviral AgentsGuanineHepatitis B virusHumansMaleAdultFemaleDouble-Blind MethodMiddle AgedHealthy VolunteersYoung AdultDNA, ViralAlanine TransaminaseCapsidTreatment OutcomeOrganophosphonates

Stichwörter der Autor:innen

antiviral efficacyfreethiadinehepatitis Bpharmacokineticssafety

Substanzen

Antiviral AgentsentecavirGuanineDNA, Viral((1-((2-amino-9H-purin-9-yl)methyl)cyclopropyl)oxy)methylphosphonic acid dipivoxylAlanine TransaminaseOrganophosphonates

Autor:innen und Institutionen

  • Phase I Clinical Trial Center, the First Hospital of Jilin University, Jilin, China.
  • Sunshine Lake Pharma Co. Ltd., Dongguan, China.
  • Enterprise Key Laboratory of Anti-Viral Drug Development, Dongguan, China.
  • Department of Hepatology, the First Hospital of Jilin University, Jilin, China.

ORCID-Profile: Junqi Niu, Yanhua Ding

Förderung

  • Sunshine Lake Pharma Co. Ltd
  • Norman Bethune Program of Jilin University
  • National Natural Science Foundation of China
  • Jilin Provincial Natural Science Foundation
  • Natural Science Foundation of Jilin Province

Zitieren

APA

Li, X., Xu, J., Sun, J., Liu, J., Wu, M., Zhang, H., Zhu, X., Li, C., Zhang, Y., Zhu, J., Chen, Y., Luo, L., He, Q., Zhuang, Y., Chen, Y., Niu, J., & Ding, Y. (2025). Safety, Pharmacokinetics and Antiviral Efficacy of Capsid Assembly Modulator Freethiadine in Healthy Volunteers and Chronic Hepatitis B Patients. Liver International. https://doi.org/10.1111/liv.16213

Vancouver

Li X, Xu J, Sun J, Liu J, Wu M, Zhang H, et al. Safety, Pharmacokinetics and Antiviral Efficacy of Capsid Assembly Modulator Freethiadine in Healthy Volunteers and Chronic Hepatitis B Patients. Liver International. 2025. doi:10.1111/liv.16213

BibTeX
@article{Li2025,
  author = {Li, Xiaojiao and Xu, Jia and Sun, Jixuan and Liu, Jingrui and Wu, Min and Zhang, Hong and Zhu, Xiaoxue and Li, Cuiyun and Zhang, Yingjun and Zhu, Jing and Chen, Yujie and Luo, Lin and He, Qingwei and Zhuang, Yulei and Chen, Yunfu and Niu, Junqi and Ding, Yanhua},
  title = {Safety, Pharmacokinetics and Antiviral Efficacy of Capsid Assembly Modulator Freethiadine in Healthy Volunteers and Chronic Hepatitis B Patients},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.16213}
}
Kostenlos starten →